Philips partners with Integron on connected health
Royal Philips and Integron, a provider of managed internet of things (IoT)...Read more on AuntMinnie.comRelated Reading: Philips introduces Ingenia Ambition X MRI scanner Philips to debut Epiq CVx scanners at ESC 2018 congress Philips grows medical sales and profit in Q2 Philips signs deal to buy EPD Solutions Philips to implement Dana-Farber's cancer support tool
AbstractPurposeObjectives of the study are to analyze the correlation between [68Ga]DOTATATE positron emission tomography (PET)/X-ray computed tomography (CT) measurements and various biological characteristics of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), and to determine optimal cutoff value of SUVmax (standard uptake value) to differentiate neuroendocrine tumors (NETs) and neuroendocrine cancers (NECs).ProceduresOf the GEP-NEN cases (73 males, 53 females; age 18 –77 years) with pathologically proven primary and/or metastatic lesions, 126 were studied. All of the short axes of lesions were lar...
Conclusion: The TLV measured on a FB plan could potentially be utilised to predict cardiac exposure and assist with patient selection for DIBH. This is important in resource allocation, as DIBH may be unnecessarily recommended for some patients with little dosimetric benefit.
Publication date: Available online 20 February 2019Source: Materials Chemistry and PhysicsAuthor(s): Fengbo Yu, Jinghua Wang, Lei Tong, Xiuping ZhangAbstractNanosized drug delivery systems are promising tools in the field of nanomedicine applied to cancer. A novel temozolidomidehydroxyapatite (TMZ/HAp) sustained-release nanopreparation for implantation in glioblastoma multiforme (GBM) patients was designed, synthesized and characterized in this study. The structure, morphology, drug loading and in vitro delivery properties of the HAp particles and the novel polysuccinimide (PSI)-coated HAp(HAp-PSI) nanoparticles were evalu...
(Johns Hopkins Medicine) In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy.
Hope et al.1 report on the impact of pretreatment 68Ga-PSMA-PET/CT or PET/MRI in the management of 45 patients with high-risk prostate cancer (PCA). Results of PSMA-PET/CTs were compared to the findings of CT scans and skeletal scintigraphy. Based on their data, PSMA-PET imaging resulted in changes of radiation therapy (RT) dose and volumes in 47% of the patients due to newly diagnosed N1/M1a disease. RT changes resulted in the extension of clinical target volume (CTV) covering the small pelvis and even the retroperitoneum or a RT boost to avid lymph nodes.
ConclusionsA quick and easy radiological assessment of sarcopenia by measuring psoas density on preoperative CT scan using software universally available in the UK is highly predictive of postoperative morbidity in colorectal cancer patients.
This study investigates the potential of using [18F]GLN positron emission tomography (PET) to monitor changes of bone marrow activity after chemotherapy (myelosuppression).ProceduresBone marrow inhibition model in mice was induced by an intravenous injection of chemotherapy drug (doxorubicin or rituximab) and the inhibition was confirmed by routine blood cell counts. Bone uptakes of these four radiotracers (2-deoxy-2-[18F]fluoro-D-glucose, [18F]GLN, 3 ′-dexoy-3′-[18F]fluorothymidine ([18F]FLT), and sodium [18F]fluoride) in the mice were measured after i.v. injection and dissection of femur and tibia, and the up...
ConclusionSimultaneous C-13 MRS/PET/mpMR imaging and multimodal image fusion-guided biopsy is feasible in a canine PCa model.
This article is protected by copyright. All rights reserved.
ConclusionsSeveral immunohistochemical markers might be helpful in predicting the response to conservative treatment of endometrial hyperplasia and early endometrial cancer on pre ‐treatment and follow‐up specimens. Further studies are needed to confirm their usefulness and possibly integrate them in a predictive immunohistochemical panel.This article is protected by copyright. All rights reserved.